Related Experiment Video
Updated: Apr 10, 2026
Robotic Lateral Pancreaticojejunostomy for Chronic Pancreatitis
Published on: December 14, 2019
Risk Factors for Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis in Patients With Post-Endoscopic
Shuhei Shibata1,2, Katsunobu Tawada1, Hideyuki Takashiro1
1Department of Gastroenterology Chiba Kaihin Municipal Hospital Chiba Japan.
Objectives:
Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is a well-known complication. While most reported risk factors relate to treatment-naïve papillae, those in patients with post-endoscopic sphincterotomy (post-EST) papillae remain unclear. We aimed to identify risk factors for PEP in patients with a history of EST undergoing ERCP for biliary disease.
Methods:
We retrospectively analyzed 678 patients with prior EST who underwent ERCP between January 2017 and October 2023. PEP was diagnosed according to established criteria. Logistic regression analyses were performed to identify risk factors. To account for repeated ERCP sessions, additional analyses using cluster-robust standard errors were conducted. Body mass index (BMI) was evaluated as both a continuous variable and according to World Health Organization categories. Prophylactic rectal diclofenac or intravenous nafamostat mesilate was administered at the operator's discretion.
Results:
The mean age was 75.4 years, and PEP occurred in 4.4%. Multivariate analysis identified female sex (p = 0.016; odds ratio [OR] 2.97), low BMI (p = 0.021; OR 2.94), and prolonged procedure time (p = 0.0048; OR 4.29) as independent risk factors. Operator experience and prophylactic agents were not significantly associated with PEP. In analyses accounting for within-patient correlation, BMI <18.5 kg/m2 remained significantly associated with PEP (OR 2.73; p = 0.012), whereas associations with sex and procedure duration were attenuated.
Conclusions:
Low BMI is a consistent risk factor for PEP in patients with post-EST papillae. The effectiveness of pharmacologic prophylaxis may differ from that in treatment-naïve papillae and warrants prospective evaluation.
Trial Registration:
N/A.
Related Concept Videos
01:26Endoscopic Procedures V: ERCP
Patient...
01:24Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:27Acute Pancreatitis I: Introduction
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
01:30Acute Pancreatitis II: Clinical Manifestations and Management
01:30Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...